Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

AngioDynamics sells PICC and Midline portfolios for $45 million

EditorLina Guerrero
Published 02/15/2024, 04:42 PM
Updated 02/15/2024, 04:42 PM
© Reuters.

LATHAM, N.Y. - Medical technology firm AngioDynamics , Inc. (NASDAQ: NASDAQ:ANGO) has divested its peripherally inserted central catheter (PICC) and Midline product lines to Spectrum Vascular for a deal that could reach $45 million. The sale, which includes a $34.5 million payment at closing, an earnout of $5.5 million, and a $5 million milestone payment, is part of the company's strategic refocus on growing its core Med Tech platforms.

The divested product lines, which also involve tip location devices, accounted for roughly $43.5 million in AngioDynamics' fiscal year 2023 revenue. Additionally, AngioDynamics has ceased the sale of its Uniblate and Starburst Radio Frequency ablation products and Syntrax support catheter products, which contributed about $5.5 million in annual sales.

President and CEO Jim Clemmer stated that this divestiture is a significant step in the company's transformation, aiming to drive growth and profitability in its NanoKnife, Mechanical Thrombectomy, and Auryon businesses. Clemmer also noted that the transaction strengthens the company's balance sheet and optimizes its product portfolio.

The sale is expected to reduce AngioDynamics' fiscal 2024 revenue by approximately $50 million but is projected to be accretive to the full-year fiscal 2024 gross margin. The company will also cut certain sales, marketing, and operational expenses in connection with the divestiture and restructuring, which is anticipated to be slightly dilutive to fiscal 2024 adjusted earnings per share.

Spectrum Vascular, the acquiring company, is a growing provider in the vascular access market. The acquisition provides them with established product lines and a skilled commercial team, which is expected to continue to serve patient needs effectively.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

AngioDynamics will provide updated fiscal 2024 financial guidance during its fiscal third-quarter earnings call in early April. UBS Investment Bank and Cadwalader, Wickersham & Taft advised AngioDynamics on the transaction, while Fried Frank acted as legal advisor to Spectrum Vascular.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.